NAFLD/NASH-related liver fibrosis: from mechanisms to prevention

Commentary

While the successful treatment of hepatitis B and C reduced the burden of liver disease related to viral hepatitis, NAFLD) or NASH) are nowadays the leading causes of hepatic fibrosis worldwide. In this review, F. Tacke et al. (Charité University Medicine, Berlin, Germany) discuss recent advances in antifibrotic prevention and therapy.

For the authors, “tackling NAFLD-associated fibrosis from different directions by combinatorial drug treatment and effective lifestyle changes hold the greatest prospects.”